Investigating DPP4's Role in Treating Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect blood and bone marrow specimens from patients with hematological malignancies to understand the effects of Dipeptidyl Peptidase-4 (DPP-4) inhibitors on acute myeloid leukemia (AML) stem cells. The research will explore how DPP-4 contributes to leukemia development and the potential for individualized therapies. By testing DPP-4 inhibitors both in vitro and in vivo, the study seeks to determine if these inhibitors can prevent AML relapse during remission. The findings may provide insights into new treatment strategies for AML and other related blood cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All hematological malignancy patients.
* Must be 18 years old.

Exclusion Criteria:

* Participants with impaired decision-making capacities;
* Pregnant women or fetuses;
* Children (under 18 in Missouri, also dependent on State law);
* Non-viable neonates or neonates of uncertain viability (neonates=newborns);
* Non-English-speaking subjects;
* Prisoners.

Where it's running

• University of Missouri
  Columbia, Missouri, United States Recruiting

Study contacts

• Study coordinator: Xunlei Kang, MD.PhD
• Email: kangxu@health.missouri.edu
• Phone: 5738844524

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Middle East study of bloodstream infections in blood cancer patients and HSCT recipients

  This is an observational study to see how bloodstream infections affect adults with blood cancers or after stem cell transplants across several Middle East countries.

  Recruiting at 9 sites Hamad Medical Corporation · Amman and 8 other locations · NCT07900542

• Withaferin A to help prevent graft-versus-host disease after stem cell transplant

  This trial tests whether adding standardized Withaferin A to standard GvHD prevention can help people 18 and older with blood cancers who are getting a matched related donor stem cell transplant.

  Recruiting at 2 sites Phase 1/2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07724873

• Standardized Withaferin A for steroid-refractory acute GVHD after stem cell transplant

  This study tests whether a standardized extract of Withania somnifera (Withaferin A) given by mouth can help patients with steroid-refractory acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07708987

• See if a behavioral coaching plus at-home exercise can help older blood cancer survivors slow aging

  Aimed at people 50 and older who have had a blood cancer, this trial tests whether combining coaching with a virtual exercise program can help slow aging and improve health.

  Recruiting University of Nebraska · Omaha, Nebraska · NCT07292272

• Using Fourth-Generation CAR-T to treat blood cancers

  This study is testing a new type of CAR-T therapy to see if it can safely help people with blood cancers like Multiple Myeloma and B-cell Lymphoma.

  Recruiting Phase 1 The Third Affiliated Hospital of Southern Medical University · Guangzhou, Guangdong · NCT06758713

• Using Thymalfasin and IL-2 to treat low lymphocyte levels in blood cancer patients

  This study is testing if a combination of two injections can help blood cancer patients with low lymphocyte levels feel better and improve their health.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06584006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.